Goresp Digihaler

Goresp Digihaler is a digital dry‑powder inhaler that delivers a fixed combination of budesonide and formoterol fumarate dihydrate. The inhaler provides inhaled corticosteroid (ICS) and long‑acting β2‑agonist (LABA) therapy in a single device, intended for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in the European market. It is a prescription‑only product and incorporates electronic dose‑counting technology to support adherence for patients requiring regular inhaled therapy.

Goresp Digihaler is indicated for the long‑term, regular treatment of two chronic respiratory conditions.

- Maintenance therapy for asthma in adults and adolescents who require both anti‑inflammatory and bronchodilator effects. - Maintenance therapy for chronic obstructive pulmonary disease (COPD) to reduce exacerbations and improve lung function. - Use as a step‑up therapy when asthma is not adequately controlled by inhaled corticosteroid alone. - Suitable for patients who prefer a digital inhaler with dose‑counting and adherence monitoring. - Can be part of a comprehensive asthma or COPD management plan that includes trigger avoidance and regular follow‑up.

Side effects of Goresp Digihaler reflect the combined actions of an inhaled corticosteroid and a long‑acting β2‑agonist.

Common: - Hoarseness or throat irritation after inhalation. - Oral candidiasis (thrush) due to local corticosteroid effect. - Cough or mild bronchospasm immediately after use. - Headache or mild dizziness. - Nasal congestion or sinus discomfort. - Transient increase in heart rate.

Serious: - Severe allergic reaction such as angioedema or anaphylaxis. - Paradoxical bronchospasm that worsens breathing. - Persistent high blood pressure or cardiac arrhythmia. - Signs of adrenal suppression with long‑term high‑dose corticosteroid use.

Before prescribing Goresp Digihaler, clinicians should consider several safety aspects.

- Assess for a history of hypersensitivity to budesonide, formoterol, or any excipients. - Use the lowest effective dose to minimize systemic corticosteroid exposure. - Monitor patients for oral thrush and advise rinsing the mouth after inhalation. - Caution in patients with cardiovascular disease, uncontrolled hypertension, or arrhythmias. - Evaluate bone health in long‑term users, especially those at risk for osteoporosis. - Advise pregnant or breastfeeding women to discuss potential risks with their healthcare provider.

Goresp Digihaler may interact with other medications that affect the cardiovascular or metabolic systems.

Avoid: - Concomitant use of non‑selective β‑blockers, which can diminish bronchodilator response. - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) that may increase systemic exposure to formoterol. - Systemic corticosteroids at high doses, which can increase risk of adrenal suppression.

Use with caution: - Diuretics or antihypertensive agents, as β2‑agonists may cause mild increases in blood pressure. - Monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants, due to potential additive cardiovascular effects. - Other inhaled or oral corticosteroids, requiring careful monitoring of total steroid load.